SEP-363856 mesylate_product_DataBase

Bioactivity	SEP-363856 (SEP-856) mesylate, an orally active TAAR1 and 5-HT1A agonist and CNS active psychotropic agent with a unique, non-D2/5-HT2A mechanism of action, exerts its antipsychotic-like effects. SEP-363856 mesylate has the potential for the study of schizophrenia[1].
Invitro	SEP-856 (10 μM) mesylate shows >50% inhibition of specific binding at α2A, α2B, D2, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C, and 5-HT7 receptors[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> SEP-363856 mesylate 相关抗体:
In Vivo	SEP-856 (0.3, 1 and 10 mg/kg, i.p.) mesylate is CNS active and exhibits a behavioral signature similar to known antipsychotic drugs[1]. SEP-856 (0.3, 1 and 10 mg/kg, orally once) mesylate significantly reduces PCP-induced hyperactivity[1]. Oral SEP-856 mesylate administration (1, 3 and 10 mg/kg) produces a dosedependent decrease in REM sleep, increase in latency to REM sleep and increase in cumulative wake (W) time[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
CAS	2375116-27-9
Formula	C10H17NO4S2
Molar Mass	279.38
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Dedic N, et al. SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action. J Pharmacol Exp Ther. 2019 Oct;371(1):1-14.

PeptideDB